A recent study assessed the therapeutic potential of IL-35 recombinant protein in a mouse model of colitis; the IL-35 treatment decreased the infiltration of macrophages, CD4+ T and CD8+ T cells and promoted the Treg cell infiltration, increased the IL-10 production and decreased IL-6, TNF-α, and IL-17A, alleviating the inflammation in acute colitis [95]. Here, IL17A is linked to colitis.